anti-CCL-9 antibody product blog
Tags: Antibody; Monoclonal Antibody; CCL-9; anti-CCL-9 antibody;
The CCL-9 ccl9 (Catalog #MBS690802) is an Antibody produced from Rat and is intended for research purposes only. The product is available for immediate purchase. The Rat Anti-Mouse CCL-9 reacts with Mouse and may cross-react with other species as described in the data sheet. MyBioSource\'s CCL-9 can be used in a range of immunoassay formats including, but not limited to, Western Blot (WB), Neutr. Researchers should empirically determine the suitability of the CCL-9 ccl9 for an application not listed in the data sheet. Researchers commonly develop new applications and it is an integral, important part of the investigative research process.The CCL-9 ccl9 product has the following accession number(s) (GI #6755434) (NCBI Accession #NP_035468.1) (Uniprot Accession #P51670). Researchers may be interested in using Bioinformatics databases such as those available at The National Center for Biotechnology Information (NCBI) website for more information about accession numbers and the proteins they represent. Even researchers unfamiliar with bioinformatics databases will find the NCBI databases to be quite user friendly and useful.
To buy or view more detailed product information and pricing, please click on the technical datasheet page below:
Mouse CCL9/10 (also named MIP1gamma and MRP2) is an 11 kDa, secreted, monomeric polypeptide that belongs to the beta (or CC) intercrine family of chemokines. Based on its activity and amino acid (aa) sequence, it is further classified as a member of the NC6 or six cysteinecontaining CC subfamily of chemokines. This subfamily contains four Nterminally extended chemokines, two human (CCL15 and CCL23) and two mouse (CCL9 and CCL10). Within this subfamily, there are no humanto rodent interspecies orthologs. Mouse CCL9/10 is synthesized as a 122 aa precursor that contains a 21 aa signal sequence and a 101 aa mature region with six cysteines. As noted, the mature region has an expanded Nterminus relative to other CC family members, and it forms a third intrachain disulfide bond with its two extra cysteines. Mouse CCL9/10 is 75% aa identical to rat CCL9/10. Chemokines are known to undergo proteolytic processing to generate multiple isoforms. NC6 chemokines are usually only marginally active at fulllength, but are converted to highly active forms upon Nterminal truncation. Mature CCL9, in the presence of inflammatory fluids, is naturally truncated by 28, 29 or 30 aa at the Nterminus, generating a highly active, 8 kDa, 71 73 aa CCR1 ligand. In contrast, other CCR1 ligands, CCL3/MIP1alpha and CCL5/RANTES, lose their potency when proteolytically processed. CCL9/10 is constitutively secreted, and circulates as a fulllength molecule. Any onset of inflammation with subsequent enzyme release may act on local NC6 chemokines, generating early, potent leukocyte chemoattractants.
Reconstitution: Reconstitute the antibody with 200 ul sterile PBS and the final concentration is 500 ug/ml. In general, we may offer more than one antibody to a given target to enable options for the researcher. Available antibodies recognizing CCL-9 are readily searchable from our website. Different antibodies against the same target such as CCL-9 may be optimized or tested for different applications and species. This enables researchers to select the option that may be best for their model system, to screen more than antibody to determine which one may be best for their model system, as well as to use more than one antibody to follow up on and validate their results.